175 related articles for article (PubMed ID: 22215228)
1. In vivo efficacy and pharmacokinetics of biapenem in a murine model of ventilator-associated pneumonia with Pseudomonas aeruginosa.
Yamada K; Yamamoto Y; Yanagihara K; Araki N; Harada Y; Morinaga Y; Izumikawa K; Kakeya H; Hasegawa H; Kohno S; Kamihira S
J Infect Chemother; 2012 Aug; 18(4):472-8. PubMed ID: 22215228
[TBL] [Abstract][Full Text] [Related]
2. In vivo efficacy of biapenem with ME1071, a novel metallo-β-lactamase (MBL) inhibitor, in a murine model mimicking ventilator-associated pneumonia caused by MBL-producing Pseudomonas aeruginosa.
Yamada K; Yanagihara K; Kaku N; Harada Y; Migiyama Y; Nagaoka K; Morinaga Y; Nakamura S; Imamura Y; Miyazaki T; Izumikawa K; Kakeya H; Hasegawa H; Yasuoka A; Kohno S
Int J Antimicrob Agents; 2013 Sep; 42(3):238-43. PubMed ID: 23891525
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of High-Dose Meropenem (Six Grams per Day) in Treatment of Experimental Murine Pneumonia Induced by Meropenem-Resistant Pseudomonas aeruginosa.
Oshima K; Nakamura S; Iwanaga N; Takemoto K; Miyazaki T; Yanagihara K; Miyazaki Y; Mukae H; Kohno S; Izumikawa K
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27799201
[TBL] [Abstract][Full Text] [Related]
4. Optimization of dose and dose regimen of biapenem based on pharmacokinetic and pharmacodynamic analysis.
Takata T; Aizawa K; Shimizu A; Sakakibara S; Watabe H; Totsuka K
J Infect Chemother; 2004 Apr; 10(2):76-85. PubMed ID: 15160299
[TBL] [Abstract][Full Text] [Related]
5. In vivo efficacy and pharmacokinetics of tomopenem (CS-023), a novel carbapenem, against Pseudomonas aeruginosa in a murine chronic respiratory tract infection model.
Morinaga Y; Yanagihara K; Nakamura S; Yamamoto K; Izumikawa K; Seki M; Kakeya H; Yamamoto Y; Yamada Y; Kohno S; Kamihira S
J Antimicrob Chemother; 2008 Dec; 62(6):1326-31. PubMed ID: 18835805
[TBL] [Abstract][Full Text] [Related]
6. In vivo efficacy of doripenem (DRPM) against Pseudomonas aeruginosa in murine chronic respiratory tract infection model.
Araki N; Yanagihara K; Morinaga Y; Yamada K; Yamada Y; Kohno S; Kamihira S
J Infect Chemother; 2011 Jun; 17(3):318-21. PubMed ID: 20972597
[TBL] [Abstract][Full Text] [Related]
7. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
Sumitani Y; Kobayashi Y
Jpn J Antibiot; 2007 Dec; 60(6):394-403. PubMed ID: 18447209
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics of carbapenems for the treatment of Pseudomonas aeruginosa ventilator-associated pneumonia: associations with clinical outcome and recurrence.
Crandon JL; Luyt CE; Aubry A; Chastre J; Nicolau DP
J Antimicrob Chemother; 2016 Sep; 71(9):2534-7. PubMed ID: 27272723
[TBL] [Abstract][Full Text] [Related]
9. [Comparative antibacterial activity of carbapenems against P. aeruginosa (1)].
Hikida M; Terashima S; Sato Y; Okamoato R; Inoue M
Jpn J Antibiot; 2001 Nov; 54(11):571-9. PubMed ID: 11828603
[TBL] [Abstract][Full Text] [Related]
10. Doripenem vs meropenem against Pseudomonas and Acinetobacter.
Goyal K; Gautam V; Ray P
Indian J Med Microbiol; 2012; 30(3):350-1. PubMed ID: 22885206
[TBL] [Abstract][Full Text] [Related]
11. [Bactericidal activity of biapenem against various bacteria].
Hiraishi T; Miyata A; Hara T; Araake M; Ogawa H
Jpn J Antibiot; 2001 Dec; 54(12):581-95. PubMed ID: 11877858
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and pharmacokinetics of ME1100, a novel optimized formulation of arbekacin for inhalation, compared with amikacin in a murine model of ventilator-associated pneumonia caused by Pseudomonas aeruginosa.
Kaku N; Morinaga Y; Takeda K; Kosai K; Uno N; Hasegawa H; Miyazaki T; Izumikawa K; Mukae H; Yanagihara K
J Antimicrob Chemother; 2017 Apr; 72(4):1123-1128. PubMed ID: 27999047
[TBL] [Abstract][Full Text] [Related]
13. [In vitro activity of biapenem (BIPM) against clinically isolated respiratory pathogens in 1996-1998].
Watanabe A; Tokue Y; Takahashi H; Kikuchi T; Kobayashi T; Gomi K; Fujimura S; Yasui S; Nukiwa T; Shoji S; Honda Y
Jpn J Antibiot; 1999 Dec; 52(12):690-4. PubMed ID: 10695024
[TBL] [Abstract][Full Text] [Related]
14. [Combined effects of arbekacin with biapenem against in vitro and in vivo model of a mixture of MRSA and Pseudomonas aeruginosa].
Niida M; Sakakibara S; Kawabata T; Maebashi K; Takata T; Hikida M
Jpn J Antibiot; 2004 Jun; 57(3):288-93. PubMed ID: 15376787
[TBL] [Abstract][Full Text] [Related]
15. Differences in antimicrobial susceptibility breakpoints for Pseudomonas aeruginosa, isolated from blood cultures, set by the Clinical and Laboratory Standards Institute (CLSI) and the Japanese Society of Chemotherapy.
Nakamura T; Shimizu C; Kasahara M; Nakata C; Munakata M; Takahashi H
J Infect Chemother; 2007 Feb; 13(1):24-9. PubMed ID: 17334725
[TBL] [Abstract][Full Text] [Related]
16. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps.
Ong CT; Tessier PR; Li C; Nightingale CH; Nicolau DP
Diagn Microbiol Infect Dis; 2007 Feb; 57(2):153-61. PubMed ID: 16930925
[TBL] [Abstract][Full Text] [Related]
17. [Antibacterial activity of biapenem against recent clinical isolates].
Hara T; Araake M; Watabe H
Jpn J Antibiot; 2003 Apr; 56(2):138-41. PubMed ID: 12825414
[TBL] [Abstract][Full Text] [Related]
18. The relationship between the daily dosage of the carbapenem meropenem (MEPM) and MEPM-resistant Pseudomonas aeruginosa.
Harashima S; Kondo H; Nabeshima A; Shimoda M; Yamaji K; Horiuchi T; Shimono N; Ikematsu H
J Infect Chemother; 2008 Jun; 14(3):219-22. PubMed ID: 18574658
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of human-simulated bronchopulmonary exposures of cefepime, zidebactam and the combination (WCK 5222) against MDR Pseudomonas aeruginosa in a neutropenic murine pneumonia model.
Kidd JM; Abdelraouf K; Nicolau DP
J Antimicrob Chemother; 2020 Jan; 75(1):149-155. PubMed ID: 31641765
[TBL] [Abstract][Full Text] [Related]
20. Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa.
Shigemi A; Matsumoto K; Yaji K; Shimodozono Y; Takeda Y; Miyanohara H; Kawamura H; Orita M; Tokuda K; Nishi J; Yamada K
Int J Antimicrob Agents; 2009 Dec; 34(6):589-91. PubMed ID: 19748231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
